We are live on ! Find out more
SM

SG3 Management Portfolio holdings

AUM $6.45K
1-Year Est. Return 61.81%
This Fund
S&P 500
This Quarter Est. Return
+11.18%
1 Year Est. Return
-61.81%
3 Year Est. Return
-38.3%
5 Year Est. Return
-6.2%
10 Year Est. Return
AUM
$2.82B
AUM Growth
-$1.18B
Cap. Flow
-$1.3B
Cap. Flow %
-46.06%
Top 10 Hldgs %
18.63%
Holding
1,492
New
367
Increased
132
Reduced
283
Closed
515

Top Buys

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$23.4M
2
AMGN icon
Amgen
AMGN
+$7.87M
3
MRNA icon
Moderna
MRNA
+$6.95M
4
PDD icon
Pinduoduo
PDD
+$5.73M
5
BAC icon
Bank of America
BAC
+$4.82M

Top Sells

Rank Stock Value
1
GOOG icon
Alphabet (Google) Class C
GOOG
+$35.8M
2
BIIB icon
Biogen
BIIB
+$9.49M
3
AON icon
Aon
AON
+$6.72M
4
RUN icon
Sunrun
RUN
+$4.78M
5
PARA
Paramount Global Class B
PARA
+$4.32M

Sector Composition

Rank Sector Weight
1 Healthcare 2.27%
2 Communication Services 1.3%
3 Consumer Discretionary 1.21%
4 Technology 1.07%
5 Financials 0.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TWNK
976
CALL
DELISTED
Hostess Brands, Inc. Class A Common Stock
TWNK
$3K ﹤0.01%
+200
New +$3.12K
CRBP icon
977
Corbus Pharmaceuticals
CRBP
$165M
$1K ﹤0.01%
17
A icon
978
Agilent Technologies
A
$39.6B
-1,000
Closed -$127K
AAL icon
979
American Airlines Group
AAL
$9.82B
-15,000
Closed -$339K
ABBV icon
980
CALL
AbbVie
ABBV
$465B
-15,000
Closed -$1.62M
ABUS icon
981
CALL
Arbutus Biopharma
ABUS
$847M
-47,500
Closed -$158K
ABUS icon
982
Arbutus Biopharma
ABUS
$847M
-11,264
Closed -$38K
ABUS icon
983
PUT
Arbutus Biopharma
ABUS
$847M
-47,500
Closed -$158K
ACAD icon
984
CALL
Acadia Pharmaceuticals
ACAD
$4.51B
-10,000
Closed -$258K
ACAD icon
985
Acadia Pharmaceuticals
ACAD
$4.51B
-10,000
Closed -$258K
ACAD icon
986
PUT
Acadia Pharmaceuticals
ACAD
$4.51B
-91,100
Closed -$2.35M
ACTG icon
987
CALL
Acacia Research
ACTG
$437M
-116,000
Closed -$771K
ADT icon
988
ADT
ADT
$5.43B
-5,500
Closed -$46K
ADV icon
989
CALL
Advantage Solutions
ADV
$575M
-1,868
Closed -$552K
AEVA
990
CALL
Aeva Technologies
AEVA
$956M
-26,000
Closed -$1.51M
AGNC icon
991
AGNC Investment
AGNC
$12.7B
-20,000
Closed -$355K
AKRO
992
CALL
DELISTED
Akero Therapeutics
AKRO
-20,000
Closed -$580K
ALL icon
993
Allstate
ALL
$70.6B
-17,000
Closed -$1.95M
ALLK
994
CALL
DELISTED
Allakos
ALLK
-30,000
Closed -$3.44M
ALLK
995
PUT
DELISTED
Allakos
ALLK
-30,000
Closed -$3.44M
ALNY icon
996
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
-12,500
Closed -$1.76M
ALT icon
997
CALL
Altimmune
ALT
$568M
-10,100
Closed -$143K
AMBA icon
998
CALL
Ambarella
AMBA
$3.04B
-10,000
Closed -$1M
AMC icon
999
PUT
AMC Entertainment Holdings
AMC
$2.45B
-750
Closed -$77K
AMRN
1000
PUT
Amarin Corp
AMRN
$297M
-475
Closed -$59K

Similar funds

SG3 Management's Q2 2021 Portfolio in Review

As of Q2 2021, SG3 Management held 1,492 positions worth $2.82B, down 30% from $4B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

SG3 Management withdrew a net $1.3B in Q2 2021, closing 515 positions and reducing 283 holdings. Its most notable exit was Alphabet (Google) Class C, an estimated $35.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 2.3% of assets, up from 1.8% a quarter earlier, followed by Communication Services and Consumer Discretionary.

Against the trend, SG3 Management opened a new position in Alphabet (Google) Class A worth $24.4M.

  • SG3 Management's largest Q2 2021 buy was Alphabet (Google) Class A: 200,000 shares worth $24.4M.
  • SG3 Management added most to Pinduoduo in Q2 2021, an estimated $5.73M increase.
  • SG3 Management's biggest Q2 2021 reduction was Paramount Global Class B, cutting an estimated $4.32M.
  • SG3 Management fully exited Alphabet (Google) Class C in Q2 2021, selling an estimated $35.8M.
  • SG3 Management's ten largest holdings make up 19% of its $2.82B portfolio in Q2 2021.
  • SG3 Management opened 367 new positions and closed 515 in Q2 2021.
  • SG3 Management's portfolio value fell 30% quarter-over-quarter to $2.82B.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.